

CITATION REPORT

List of articles citing

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

DOI: 10.1016/j.cjca.2016.07.510

Canadian Journal of Cardiology, 2016, 32, 1263-1282.

Source: <https://exaly.com/paper-pdf/64606124/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
658	Statins for primary prevention of cardiovascular disease. 2016 , 355, i6334		9
657	Bringing Structure to the Art of Lipid-Lowering Therapy. 2016 , 68, 2422-2424		1
656	Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. 2016 , 7, 679-693		10
655	Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 872-882	3.8	26
654	Rational Medical Therapy Is the Key to Effective Cardiovascular Disease Prevention. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 626-634	3.8	2
653	Proportion of adults fasting for lipid testing relative to guideline changes in Alberta. 2017 , 50, 344-346		1
652	Genetics for the Identification of Lipid Targets Beyond PCSK9. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 334-342	3.8	7
651	The association between insomnia symptoms and cardiovascular risk factors in patients who complete outpatient cardiac rehabilitation. 2017 , 32, 201-207		13
650	Statin Prescriptions for High-Risk Patients Are Increased by Laboratory-Initiated Framingham Risk Scores: A Quality-Improvement Initiative. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 682-684	3.8	5
649	Apolipoprotein B vs non-high-density lipoprotein cholesterol: Association with endothelial hemostatic markers and carotid intima-media thickness. 2017 , 11, 442-449		1
648	Precision of nonfasting lipid profiles should focus on clinical relevance rather than necessarily obtaining the least variation. 2017 , 55, e189-e190		1
647	Glycemic index is as reliable as macronutrients on food labels. 2017 , 105, 768-769		12
646	A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. 2017 , 69, 692-711		396
645	Reply to TMS Wolever et al. 2017 , 105, 769-770		1
644	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. 2017 , 135, 1819-1831		52
643	Sex Differences in Cardiac Medication Use Post-Catheterization in Patients Undergoing Coronary Angiography for Stable Angina with Nonobstructive Coronary Artery Disease. 2017 , 26, 976-983		5
642	Rates of inappropriate laboratory test utilization in Ontario. 2017 , 50, 822-827		27

641	Lipoprotein(a): new insights from modern genomics. 2017 , 28, 170-176		17
640	LDL particle number and size and cardiovascular risk: anything new under the sun?. 2017 , 28, 261-266		15
639	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. 2017 , 263, 112-118		3
638	Statin Prescribing Practices in the Comprehensive Care for HIV-Infected Patients. 2017 , 76, e26-e29		15
637	Bioaccessibility and bioavailability of phenolic compounds in bread: a review. 2017 , 8, 2368-2393		70
636	Remnant lipoproteins. 2017 , 28, 300-307		49
635	The Evolution of Targeted Interventions in the Age of Precision Medicine. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 597-600	3.8	
634	Cardiac Medication Use in Patients with Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease. 2017 , 26, 1185-1192		5
633	Seeking 'meta guidelines' for lipids. 2017 , 24, 72-75		1
632	The Effect of Triglyceride Concentration on Attainment of Lipid Targets in Patients with Diabetes. 2017 , 41, 380-384		2
631	A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. 2017 , 105, 1239-1247		43
630	Statins for primary prevention of cardiovascular disease : Patients need better tools to navigate divergent recommendations. 2017 , 103, 477-478		5
629	Dyslipidemia in patients with chronic kidney disease. 2017 , 18, 29-40		75
628	Familial Hypercholesterolemia: Awareness, Appraisal, and Action. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 298-299	3.8	4
627	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 343-349	3.8	13
626	Optimal Low-Density Lipoprotein Cholesterol for Cardiovascular Prevention: How Low Should We Go?. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 405-408	3.8	2
625	Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1305-1311	3.8	11
624	Effect of a low glycemic index diet versus a high-cereal fibre diet on markers of subclinical cardiac injury in healthy individuals with type 2 diabetes mellitus: An exploratory analysis of a randomized dietary trial. 2017 , 50, 1104-1109		5

623	Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases?. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1513-1516	3.8	1
622	Review of the top 5 cardiology studies of 2015-16. 2017 , 150, 380-386		2
621	A Test in Context: Lipid Profile, Fasting Versus Nonfasting. 2017 , 70, 1637-1646		93
620	Clinical Features and Outcomes of Acute Coronary Syndrome in Women With Previous Pregnancy Complications. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1683-1692	3.8	12
619	Disparities in hypertension and cardiovascular disease in blacks: The critical role of medication adherence. 2017 , 19, 1015-1024		72
618	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. 2017 , 131, 1373-1381		92
617	Importance of Optimization of Cardiovascular Risk Factors and Lifestyle Behaviours. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1221-1222	3.8	3
616	Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors. 2017 , 318, 419-420		8
615	2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. 2017 , 150, 243-250		5
614	Risk of misclassification with a non-fasting lipid profile in secondary cardiovascular prevention. 2017 , 472, 90-95		4
613	Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. 2017 , 17, 870-878.e1		20
612	Evolocumab for the treatment of hypercholesterolemia. 2017 , 17, 1447-1461		2
611	Statin therapy: time for a precision medicine approach?. 2017 , 2, 187-192		0
610	Association of the TG/HDL-C and Non-HDL-C/HDL-C Ratios with Chronic Kidney Disease in an Adult Chinese Population. 2017 , 42, 1141-1154		22
609	Cardiovascular Disease Risk Assessment in the United States and Low- and Middle-Income Countries Using Predicted Heart/Vascular Age. 2017 , 7, 16673		8
608	Propuesta personal de actualización para el tratamiento de la hipercolesterolemia en Colombia. 2017 , 24, 25-31		
607	An evaluation of CardioPrevent: a technology-enabled, health-behavior change program for the global reduction of cardiovascular risk. <i>Current Opinion in Cardiology</i> , 2017 , 32, 580-589	2.1	2
606	What's in a Number? Risk Thresholds in Different Statin Guidelines. 2017 , 32, 1071-1073		1

605	The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience. <i>Current Opinion in Cardiology</i> , 2017 , 32, 633-641 ^{2.1}	2.1	1
604	Effective Management of Cardiovascular Risk Factors-Are We Doing Enough?. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 300-302	3.8	1
603	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 325-333	3.8	30
602	Prevention of Cardiovascular Disease Among Cancer Survivors: the Role of Pre-existing Risk Factors and Cancer Treatments. 2017 , 4, 239-247		6
601	Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2017 , 6,		46
600	A Clinical Study of Lipid Abnormalities and Angiographic Profile in Patients of Coronary Artery Disease on Statins Undergoing Coronary Angiography. 2017 , 02, 011-018		
599	An Appetite for Modernizing the Regulatory Framework for Protein Content Claims in Canada. 2017 , 9,		5
598	Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. 2017 , 13, 293-303		41
597	Ronda clínica y epidemiológica: club de revistas. 2017 , 30, 463-471		
596	Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. 2018 , 138, 244-254		26
595	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1004-1009	3.8	16
594	Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines - Executive summary: A consensus endorsed by the Cardiovascular Risk and Prevention Group of the Portuguese Internal Medicine Society, the Portuguese Atherosclerosis Society, the Portuguese Society of Cardiology, the Portuguese Society of Laboratory Medicine and the Portuguese Association of Clinical Chemistry. 2018 , 37, 279-283		2
593	Dyslipidemia. 2018 , 42 Suppl 1, S178-S185		26
592	Nutrition Therapy. 2018 , 42 Suppl 1, S64-S79		57
591	Prevention and management of statin adverse effects: A practical approach for pharmacists. 2018 , 151, 179-188		9
590	Statin guidelines: Friend or foes?. 2018 , 25, 867-869		
589	Cardiovascular Protection in People With Diabetes. 2018 , 42 Suppl 1, S162-S169		30
588	The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. 2018 , 41, 888-895		8

587	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. 2018 , 36, 287-298		10
586	A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. 2018 , 22, 241-254		6
585	Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. 2018 , 168, 85-92		41
584	Lessons from animal nutritionists: dietary amino acid requirement studies and considerations for healthy aging studies. 2018 , 1418, 20-30		3
583	Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic. 2018 , 48, 201-204		1
582	A Comparative Analysis of Current Lipid Treatment Guidelines: Nothing Stands Still. 2018 , 71, 794-799		15
581	Research in Women's Cardiovascular Health-Progress at Last?. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 349-353	3.8	2
580	Primary Prevention With Statins in the Elderly. 2018 , 71, 85-94		77
579	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 595-604	3.8	37
578	Dyslipidaemia in the elderly: to treat or not to treat?. 2018 , 11, 259-278		5
577	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. 2018 , 71, 177-192		203
576	LDL cholesterol: How low to go?. 2018 , 28, 348-354		8
575	The year in cardiology 2017: prevention. 2018 , 39, 345-353		3
574	High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome. 2018 , 59, 300-306		6
573	Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?. 2018 , 41, 333-338		1
572	Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: Is it time to change?. 2018 , 274, 243-250		3
571	How does the TRS 2°P score relate to real-world patients?. 2018 , 4, 72-74		3
570	Lipids and Lipoproteins in Risk Prediction. 2018 , 36, 213-220		5

569	Comment: Should an LDL Cholesterol Target-Based Approach Be Readopted?. 2018 , 52, 706-707		1
568	Managing dyslipidaemia for the primary prevention of cardiovascular disease. 2018 , 360, k946		4
567	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. 2018 , 42, 23-30		12
566	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. 2018 , 64, 355-362		32
565	Role of new imaging modalities in pursuit of the vulnerable plaque and the vulnerable patient. 2018 , 250, 278-283		8
564	Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled REACH Trial. 2018 , 71, 42-51		13
563	Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. 2018 , 13, 420-443		119
562	Canadian stroke best practice consensus statement: Secondary stroke prevention during pregnancy. 2018 , 13, 406-419		20
561	Effects of stress on the development and progression of cardiovascular disease. 2018 , 15, 215-229		345
560	Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. 2018 , 52, 61-66		20
559	A Comparative Study of Muscle Symptoms of Atorvastatin with Rosuvastatin in Patients of Atherosclerotic Cardiovascular Disease. 2018 , 14, 9-20		
558	Nonfasting lipid testing: the new standard for cardiovascular risk assessment. 2018 , 190, E1317-E1318		5
557	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1553-1563	3.8	58
556	Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis. 2018 , 17, 277		7
555	Poor Adherence to Dietary Guidelines Among French-Speaking Adults in the Province of Quebec, Canada: The PREDISE Study. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1665-1673	3.8	19
554	Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1600-1605	3.8	18
553	Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. 2018 , 72, 2980-2995		9
552	The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation. 2018 , 29, 436-444		15

551	Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. 2018 , 12, 1		2
550	Lipoprotein(a): lodestar for future clinical trials. 2018 , 392, 1281-1282		8
549	LDL-Cholesterol Lowering of Plant Sterols and Stanols-Which Factors Influence Their Efficacy?. 2018 , 10,		38
548	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. 2018 , 190, E1192-E1206		16
547	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1371-1392	3.8	144
546	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice. 2018 , 2018, 1528437		6
545	Lipid management in patients with chronic kidney disease. 2018 , 14, 727-749		82
544	Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. 2018 , 7, e008657		48
543	Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. 2018 , 7, e009745		18
542	Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. 2018 , 22, 641-652		1
541	Effect of psyllium (<i>Plantago ovata</i>) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. 2018 , 108, 922-932		19
540	Incidence and magnitude of post-transplant cardiovascular disease after pediatric kidney transplantation: Risk factor analysis of 1058 pediatric kidney transplants at the university of Minnesota. 2018 , 22, e13283		3
539	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. 2018 , 45, 1426-1439		33
538	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. 2018 , 64, 1006-1033		124
537	Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. 2018 , 8, 7726		21
536	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1210-1214	3.8	36
535	Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. 2018 , 61, 43-53		64
534	Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines - Full report. 2018 , 31, e1-e12		16

533	Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. 2018 , 7,		9
532	Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 959-961	3.8	4
531	Navigating the highlights of EAS Congress Lisbon. 2018 , 275, 387-389		
530	The Role of Nutraceuticals in Statin Intolerant Patients. 2018 , 72, 96-118		157
529	Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. 2018 , 276, 10-14		20
528	Quality of care for cardiovascular disease prevention in rheumatoid arthritis: compliance with hyperlipidemia screening guidelines. 2018 , 57, 1789-1794		9
527	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. 2018 , 39, 2589-2596		56
526	Pediatric reference intervals for calculated LDL cholesterol, non-HDL cholesterol, and remnant cholesterol in the healthy CALIPER cohort. 2018 , 486, 129-134		5
525	Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT). 2018 , 190, E871-E882		19
524	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1350-1361	3.8	2
523	Nutritional Requirements of Lung Transplant Recipients: Challenges and Considerations. 2018 , 10,		16
522	Coronary Calcium Score and Cardiovascular Risk. 2018 , 72, 434-447		309
521	Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. 2018 , 28, 980-986		19
520	Prenatal biochemical screening and long term risk of maternal cardiovascular disease: population based cohort study. 2018 , 362, k2739		3
519	Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. 2018 , 41, 1328-1335		21
518	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. 2018 , 20, 88		10
517	Comparison Shopping: Guidelines for Statins for Primary Prevention of Cardiovascular Disease. 2018 , 168, 145-146		1
516	Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. 2018 , 72, 1141-1156		126

515	The Cardiovascular Burden of Undiagnosed Familial Hypercholesterolemia: Need to Modify Guidelines to Encourage Earlier Diagnosis and Therapy. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1112-1118	3
514	Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. 2018 , 12, 1313-1323	38
513	Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts. 2018 , 18, 97	13
512	Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study. 2018 , 6, 705-713	61
511	Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction. 2018 , 484, 232-236	8
510	The economic burden of not meeting food recommendations in Canada: The cost of doing nothing. 2018 , 13, e0196333	32
509	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. 2018 , 75, 747-754	2
508	Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines [Executive summary]. 2018 , 37, 279-283	2
507	Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 590-597	3.8 2
506	Dyslipidemia in Diabetes. 2019 , 186-198	2
505	Human high-density lipoprotein microtranscriptome is unique and suggests an extended role in lipid metabolism. 2019 , 11, 917-934	4
504	Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations. 2019 , 8, e012228	16
503	Development and validation of a Brief Diet Quality Assessment Tool in the French-speaking adults from Quebec. 2019 , 16, 61	2
502	Lp(a): Addressing a Target for Cardiovascular Disease Prevention. 2019 , 21, 102	10
501	Lipoprotein(a) and coronary artery disease in Chinese postmenopausal female patients: a large cross-sectional cohort study. 2019 , 95, 534-540	4
500	Prognostic implications of statin intolerance in stable coronary artery disease patients with different levels of high-sensitive troponin. 2019 , 19, 168	2
499	Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 884-891	3.8 16
498	Premature Atherosclerotic Cardiovascular Disease: Trends in Incidence, Risk Factors, and Sex-Related Differences, 2000 to 2016. 2019 , 8, e012178	30

497	Postpartum Cardiovascular Prevention: The Need for a National Health Systems-Based Strategy. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 701-704	3.8	1
496	Cumulative Meta-Analysis of the Soy Effect Over Time. 2019 , 8, e012458		12
495	Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. 2019 , 58, 2333-2335	8	
494	Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors. 2019 , 26, 199-207		9
493	Goals of non-high density lipoprotein cholesterol need to be adjusted in Chinese acute coronary syndrome patients: Findings from the CCC-ACS project. 2019 , 496, 48-54		9
492	Relation of Vegetarian Dietary Patterns With Major Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. 2019 , 6, 80		30
491	HEART UK consensus statement on Lipoprotein(a): A call to action. 2019 , 291, 62-70		56
490	Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses. 2019 , 50, 285-294		44
489	Chronic Kidney Disease Diagnosis and Management: A Review. 2019 , 322, 1294-1304		252
488	Risks of Dysglycemia Over the First 4 Years After a Hypertensive Disorder of Pregnancy. 2019 , 43, 587-593		0
487	Catering to Your Concerns. 2019 , 3, 1-21		1
486	Treatment with Statins in Elderly Patients. 2019 , 55,		16
485	Measurement of lipid profiles in the early postpartum period after hypertensive disorders of pregnancy. 2019 , 13, 1008-1015		2
484	2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2019 , 12, e000057		22
483	Associations between Dietary Pulses Alone or with Other Legumes and Cardiometabolic Disease Outcomes: An Umbrella Review and Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. 2019 , 10, S308-S319		31
482	Au-delà du risque cardiovasculaire : le rôle des lipoprotéines contenant l'apoB athérogènes dans l'étiologie du diabète de type 2. 2019 , 13, 129-139		2
481	Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. 2019 , 33, 739-748		14
480	Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. 2019 , 4, 969-977		11

479	Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials. 2019 , 4, 1160-1169		12
478	CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia. 2019 , 38, 531-542		2
477	Lipid findings from the Diabetes Education to Lower Insulin, Sugars, and Hunger (DELISH) Study. 2019 , 16, 58		4
476	Chagas Disease. 2019 ,		6
475	Prevalence of chronic kidney disease and cardiovascular comorbidities in adults in First Nations communities in northwest Ontario: a retrospective observational study. 2019 , 7, E568-E572		9
474	Comparison of metabolic and antioxidant responses to a breakfast meal with and without pecans. 2019 , 62, 103559		4
473	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. 2019 , 1, 190-197		2
472	Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying Appraisal of Guidelines for Research and Evaluation II-clinical practice guideline appraisal for lipid management in coronary heart disease. 2019 , 11, 3534-3546		6
471	Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. 2019 , 4, 1131-1138		26
470	Smashing Low-Density Lipoprotein Levels and Preventing Coronary Allograft Vasculopathy: One Heart Transplant Patient at a Time. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 17-18	3.8	1
469	F-Sodium Fluoride Imaging of Coronary Atherosclerosis in Ambulatory Patients With Diabetes Mellitus. 2019 , 39, 276-284		21
468	Worldwide Dyslipidemia Guidelines. 2019 , 13, 1		7
467	To Risk Stratify or Not for Statin Therapy. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 550-551	3.8	
466	The Cat Has 9 Lives, Until it Dies. 2019 , 73, 397-399		1
465	Cholesterol-Lowering Agents. 2019 , 124, 354-363		17
464	Statin Use and Chronic Lymphocytic Leukemia Incidence: A Nested Case-Control Study in Manitoba, Canada. 2019 , 28, 1495-1501		4
463	Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease. 2019 , 82, 101-105		2
462	Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. 2019 , 18, 134		21

461	Cardiovascular Disease Risk Across a Spectrum of Adverse Plasma Lipid Combinations by Gender and Glycemic Status. 2019 , 124, 702-708		3
460	Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. 2019 , 179, 898-905		30
459	New Insights into the Association between Fibrinogen and Coronary Atherosclerotic Plaque Vulnerability: An Intravascular Optical Coherence Tomography Study. 2019 , 2019, 8563717		5
458	Deteriorated Cardiometabolic Risk Profile in Individuals With Excessive Blood Pressure Response to Submaximal Exercise. 2019 , 32, 945-952		4
457	Referral to Cardiology Following Postpartum Cardiovascular Risk Screening at the Maternal Health Clinic in Kingston, Ontario. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 761-769	3.8	6
456	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. 2019 , 71, 1651-1659		15
455	Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study. 2019 , 70, 819-829		8
454	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. 2019 , 13, 374-392		156
453	Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes. 2019 , 42, 1312-1318		50
452	Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes. 2019 , 2019, 5931975		5
451	Comparison of non-fasting LDL-C levels calculated by Friedewald formula with those directly measured in Chinese patients with coronary heart disease after a daily breakfast. 2019 , 495, 399-405		12
450	Clinical Utility and Practical Considerations of a Coronary Artery Disease Genetic Risk Score. 2019 , 1, 69-75		3
449	Guideline Alignment in Related Areas. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 606-610	3.8	0
448	A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults. 2019 , 149, 968-981		36
447	Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines. 2019 , 36, 687-699		18
446	Cardiovascular Risks Associated with Gender and Aging. <i>Journal of Cardiovascular Development and Disease</i> , 2019 , 6,	4.2	132
445	The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 558-563	3.8	
444	Effect of PolyGlycopleX (PGX) Consumption on Blood Lipid Profiles in Healthy, Low CVD Risk Overweight Adults. 2019 , 11,		1

443	Psychosocial Stress and Cardiovascular Disease. 2019 , 21, 23		41
442	Effects of Preoperative Statin on Acute Kidney Injury After Off-Pump Coronary Artery Bypass Grafting. 2019 , 8, e010892		8
441	A Randomized Clinical Efficacy Trial of Red Yeast Rice (<i>Monascus pilosus</i>) Against Hyperlipidemia. 2019 , 47, 323-335		6
440	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 140, e596-e646		898
439	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. 2019 , 56, 338-356		18
438	Potential impacts of climate-related decline of seafood harvest on nutritional status of coastal First Nations in British Columbia, Canada. 2019 , 14, e0211473		13
437	Non-invasive measurements of arterial function: What? When? Why should we use them?. 2019 , 105, 1203-1211		5
436	In Search of Patients With Elevated Lp(a): Seek and Ye Shall Find. 2019 , 73, 1040-1042		3
435	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 644-652	3.8	0
434	To test, or not to test: that is the question for the future of lipoprotein(a). 2019 , 17, 241-250		4
433	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. 2019 , 40, 537-557		109
432	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 74, e177-e232		516
431	Sex differences in psychosocial and cardiometabolic health among patients completing cardiac rehabilitation. 2019 , 44, 1237-1245		6
430	Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications. 2019 , 144, 116-131		8
429	Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. 2019 , 15, 137-145		4
428	Cardiovascular Risk Assessment and Follow-Up of Women After Hypertensive Disorders of Pregnancy: A Prospective Cohort Study. 2019 , 41, 1157-1167.e1		9
427	Cardiovascular Risk Reduction in the Workplace With CAMMPUS (Cardiovascular Assessment and Medication Management by Pharmacists at the UBC Site). 2019 , 53, 574-580		5
426	How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. 2019 , 94, 660-669		5

425	Identifying and managing younger women at high risk of cardiovascular disease. 2019 , 191, E159-E163	5
424	DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. 2019 , 11,	144
423	Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines. 2019 , 5, 87-97	
422	Feasibility and implementation of a healthy lifestyles program in a community setting in Ontario, Canada: protocol for a pragmatic mixed methods pilot study. 2019 , 9, e031298	
421	Trends in cardiovascular care and event rates among First Nations and other people with diabetes in Ontario, Canada, 1996-2015. 2019 , 191, E1291-E1298	8
420	Age-specific and sex-specific reference intervals for non-fasting lipids and apolipoproteins in 7260 healthy Chinese children and adolescents measured with an Olympus AU5400 analyser: a cross-sectional study. 2019 , 9, e030201	2
419	2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 2019 , 74, 2661-2706	18
418	Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. 2019 , 1, 297-304	
417	The intestinal microbiota regulates host cholesterol homeostasis. 2019 , 17, 94	60
416	Comparison of Cardiovascular Risk Factors and Outcomes Among Practicing Physicians vs the General Population in Ontario, Canada. 2019 , 2, e1915983	0
415	Economic Burden of Not Complying with Canadian Food Recommendations in 2018. 2019 , 11,	6
414	Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent Guidelines. 2019 ,	5
413	Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. 2019 , 94, 2399-2414	22
412	CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia. 2019 , 38, 531-542	1
411	Pregnancy and the Postpartum Period as an Opportunity for Cardiovascular Risk Identification and Management. 2019 , 134, 851-862	40
410	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1 9
409	Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. 2019 , 281, 25-30	20
408	Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. 2019 , 51, 148-154	49

407	Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. 2019 , 40, 621-631	52
406	Novel biomarkers of cardiovascular disease: Applications in clinical practice. 2019 , 56, 33-60	37
405	Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. 2019 , 10, 401-408	3
404	Drug Therapy of Dyslipidemia in the Elderly. 2019 , 36, 321-340	13
403	A core outcome set for clinical trials of Chinese medicine for hyperlipidemia: a study protocol for a systematic review and a Delphi survey. 2019 , 20, 14	5
402	Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. 2019 , 13, 138-147	10
401	Non-traditional lipid profiles associated with ischemic stroke not hemorrhagic stroke in hypertensive patients: results from an 8.4 years follow-up study. 2019 , 18, 9	9
400	Dyslipidaemia in adults with type 1 diabetes-when to treat?. 2019 , 35, e3090	4
399	Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. 2019 , 170, 1-10	32
398	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. 2019 , 51, 131-141	74
397	Association of total cholesterol with severe acute pancreatitis: A U-shaped relationship. 2020 , 39, 250-257	10
396	Cardiovascular Disease Prognostic Models in Latin America and the Caribbean: A Systematic Review. 2019 , 14, 81-93	5
395	Dyslipidemia Management in Adults With Diabetes. 2020 , 44, 53-60	19
394	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. 2020 , 6, 104-114	14
393	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. 2020 , 57, 16-23	5
392	Moving Toward Sex-Specific Cardiovascular Risk Estimation. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 13-15	3.8 2
391	Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. 2020 , 40, 267-278	37
390	Impact of the Martin/Hopkins modified equation for estimating LDL-C on lipid target attainment in a high risk patient population. 2020 , 76, 35-37	7

389	Inclisiran-New hope in the management of lipid disorders?. 2020 , 14, 16-27	45
388	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. 2020 , 58, 496-517	50
387	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. 2020 , 8, 36-49	58
386	The Power of Diet in CVD Risk Factor Reduction. 2020 , 1-16	
385	Development and Evidence Base. 2020 , 17-28	
384	Cardiometabolic responses to cardiac rehabilitation in people with and without diabetes. 2020 , 301, 156-162	2
383	Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. 2020 , 287, 2-18	44
382	:"""". 2020 , 78, 67-76	
381	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). 2020 , 61, 1263-1270	5
380	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale [®]). 2020 , 32, 219-229	0
379	Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound. 2020 , 126, 104043	15
378	A Patient-Led Referral Strategy for Cardiovascular Screening of Family and Household Members at the Time of Cardiac Intensive Care Unit Admission. 2020 , 2, 506-513	1
377	Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. 2020 , 2, 530-538	7
376	Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers. 2020 , 14, 825-836	1
375	Early postpartum dyslipidemia and its potential predictors during pregnancy in women with a history of gestational diabetes mellitus. 2020 , 19, 220	0
374	Comprehensive laboratory reference intervals for routine biochemical markers and pro-oxidant-antioxidant balance (PAB) in male adults. 2020 , 34, e23470	4
373	Management of hypertriglyceridemia. 2020 , 371, m3109	28
372	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale [®]). 2020 , 32, 219-229	2

371	Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation. 2020 , 15, e0239934	7
370	Evaluating the diagnostic and prognostic value of biomarkers for heart disease and major adverse cardiac events in patients with muscular dystrophy. 2021 , 7, 564-573	3
369	Optimizing screening and management of cardiovascular health in prostate cancer: A review. 2020 , 14, E458-E464	1
368	A cautionary tale: Is this APOB whole-gene duplication actually pathogenic?. 2020 , 14, 631-635	1
367	Prolonged hyperlipidemia exposure increases the risk of arterial stiffness in young adults: a cross-sectional study in a cohort of Chinese. 2020 , 20, 1091	2
366	Lipids and lipoproteins. 2020 , 487-506	1
365	The Association of Syntax Score with Levels of Lipoprotein(a) and Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease and Different Low-Density Lipoprotein Cholesterol Levels. 2020 , 13, 4297-4310	1
364	Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk Markers. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1 1
363	The U.S. Department of Veterans Affairs and U.S. Department of Defense Guideline for the Management of Dyslipidemia: Is Moderate Risk Reduction Enough?. 2020 , 173, 846-847	
362	Development of a cost-effective CVD prediction model using lifestyle factors. A cohort study in Pakistan. 2020 , 20, 849-859	
361	Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. 2020 , 6, e12108	13
360	Relationship of healthy vascular aging with lifestyle and metabolic syndrome in the general Spanish population. The EVA study. 2021 , 74, 854-861	
359	The Role of Statins in Current Guidelines. 2020 , 22, 50	8
358	Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. 2020 , 310, 54-63	4
357	The Role of Carotid and Femoral Plaque Burden in the Diagnosis of Coronary Artery Disease. 2020 , 22, 121	2
356	What is the best diet for cardiovascular wellness? A comparison of different nutritional models. 2020 , 10, 50-61	7
355	Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?. 2020 , 12,	11
354	Low-carbohydrate diets and cardiometabolic health: the importance of carbohydrate quality over quantity. 2020 , 78, 69-77	24

353	Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. 2020 , 2, 100040	
352	"The Child Is the Father of the Man"-Pediatric Preventive Cardiology. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1329-1332	3.8
351	Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. 2020 , 2, 100036	1
350	Mnemonic to assist in the treatment of NSTEMI-ACS. 2020 , 45, 48-55	1
349	Enhanced long-term dietary change and adherence in a nutrigenomics-guided lifestyle intervention compared to a population-based (GLB/DPP) lifestyle intervention for weight management: results from the NOW randomised controlled trial. 2020 , 3, 49-59	13
348	The Role of Specific Components of a Plant-Based Diet in Management of Dyslipidemia and the Impact on Cardiovascular Risk. 2020 , 12,	36
347	Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study. 2020 , 20, 418	1
346	Ultrasound-based stroke/cardiovascular risk stratification using Framingham Risk Score and ASCVD Risk Score based on "Integrated Vascular Age" instead of "Chronological Age": a multi-ethnic study of Asian Indian, Caucasian, and Japanese cohorts. 2020 , 10, 939-954	8
345	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. 2020 , 105,	26
344	Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study. 2020 , 17, e1003280	1
343	Evaluation of Glycemic Index Education in People Living with Type 2 Diabetes: Participant Satisfaction, Knowledge Uptake, and Application. 2020 , 12,	1
342	A RARE CASE OF STATIN-INDUCED NECROTIZING AUTOIMMUNE MYOPATHY. 2020 , 6, e86-e89	0
341	Cardiovascular risk assessment in patients with rheumatoid arthritis using carotid ultrasound B-mode imaging. 2020 , 40, 1921-1939	7
340	Healthcare Cost Implications of Utilizing a Dietary Intervention to Lower LDL Cholesterol: Proof of Concept Actuarial Analysis and Recommendations. 2020 , 22, 138	
339	Optimizing Cholesterol Management Improves the Benefits of Percutaneous Coronary Intervention. 2020 , 76, 1451-1454	0
338	Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study. 2020 , 9, e014711	10
337	Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment. 2020 , 13, 623-632	4
336	Cardiovascular/stroke risk predictive calculators: a comparison between statistical and machine learning models. 2020 , 10, 919-938	31

335	Frequency of laboratory testing and associated abnormalities in patients with hypertension. 2020 , 22, 2077-2083	1
334	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. 2021 , 121, 1161-1168	1
333	Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners' perspectives on a facilitated relay intervention in Alberta, Canada. 2020 , 10, e038469	1
332	Addressing atherosclerotic cardiovascular disease risk in South Asians: A daunting task ahead. 2020 , 315, 76-78	1
331	Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists. 2020 , 2, 625-631	0
330	Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results. 2020 , 170, 108-117	0
329	Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults. 2020 , 9, e018233	2
328	Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. 2020 , 34, 515-523	2
327	Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study. 2020 , 2020, 7026530	0
326	Cardiovascular Risk in Individuals with Inflammatory Bowel Disease. 2020 , 13, 107-113	16
325	Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration. 2020 , 19, 98	0
324	Lipids and Diabetes. 2020 , 1-6	0
323	Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists. 2020 , 153, 153-160	0
322	Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry. 2020 , 76, 385-394	3
321	Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT. 2020 , 22, 1722-1728	4
320	Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations. 2020 , 192, E442-E449	6
319	Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. 2020 , 52, 162-177	13
318	Guidelines about physical activity and exercise to reduce cardiometabolic risk factors: protocol for a systematic review and critical appraisal. 2020 , 10, e032656	5

317	Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease. 2020 , 69, 197-205		2
316	Association of Dietary Phytosterols with Cardiovascular Disease Biomarkers in Humans. 2020 , 55, 569-584		13
315	Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. 2020 , 22, 67		17
314	The Rationale, Indications, Safety, and Use of Statins in the Pediatric Population. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1372-1383	3.8	1
313	Rate of dyslipidemia higher among women living with HIV: A comparison of metabolic and cardiovascular health in a cohort to study aging in HIV. 2020 , 21, 418-428		8
312	GOAL Canada: Physician Education and Support Can Improve Patient Management. 2020 , 2, 49-54		2
311	Effect of soluble-viscous dietary fibre on coronary heart disease risk score across 3 population health categories: data from randomized, double-blind, placebo-controlled trials. 2020 , 45, 801-804		1
310	The dedicated "Lp(a) clinic": A concept whose time has arrived?. 2020 , 300, 1-9		24
309	Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. 2020 , 33, 917-933		47
308	Renal Medicine and Clinical Pharmacy. 2020 ,		0
307	Baseline, delta, and achieved low-density lipoprotein cholesterol levels and cardiovascular risk in patients on statin therapy: A post-hoc resampling mediation analysis of treating new targets [TNT] trial. 2020 , 47, 1649-1658		1
306	Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study. 2020 , 2047487320905722		7
305	A simple aptamer-based colorimetric assay for rapid detection of C-reactive protein using gold nanoparticles. 2020 , 214, 120868		32
304	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. 2020 , 27, 1663-1674		1
303	Subclinical Hypothyroidism with TSH>7 mIU/l and 10 mIU/l and Coronary Artery Disease. 2020 , 52, 85-88		5
302	Non-Fasting Triglyceride Levels as a Superior Predictor of Cardiovascular Disease. 2020 , 84, 386-387		2
301	Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. 2020 , 33, 417-430		6
300	Making Informed CHOICES: The Launch of a "Big Data" Pragmatic Trial to Improve Cholesterol Management and Prevent Heart Disease in Ontario. 2020 , 22, 6-9		0

299	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). 2020 , 155, 104719	7
298	Cardiac Intervention Improves Heart Disease and Clinical Outcomes in Patients With Muscular Dystrophy in a Multidisciplinary Care Setting. 2020 , 9, e014004	8
297	Statin-Associated Muscle Symptoms. 2020 ,	
296	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. 2020 , 17, 360-377	41
295	Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study. 2020 , 19, 5	5
294	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. 2020 , 294, 46-61	49
293	Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. 2020 , 9, e014581	13
292	Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia. 2020 , 4, bvz010	3
291	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. 2020 , 2, 402-415	0
290	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. 2020 , 222, 787-797	4
289	More accurate LDL-C calculation: Externally validated, guideline endorsed. 2020 , 506, 149-153	15
288	Effects of fatty acids composition in a breakfast meal on the postprandial lipid responses: a systematic review and meta-analysis of randomised controlled trials. 2020 , 71, 793-803	4
287	2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. 2020 , 41, 3005-3015	17
286	Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. 2020 , 41, 2288-2299	28
285	Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. 2020 , 43, 1157-1163	12
284	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. 2020 , 141, e779-e806	58
283	Outcome and Cost of Optimal Control of Dyslipidemia in Adults With High Risk for Cardiovascular Disease. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 66-76	3.8 1
282	Dietary habits, lipoprotein metabolism and cardiovascular disease: From individual foods to dietary patterns. 2021 , 61, 1651-1669	10

281	Comparing Risk Scores in the Prediction of Coronary and Cardiovascular Deaths: Coronary Artery Calcium Consortium. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 411-421	8.4	16
280	Practical Guidance for Food Consumption to Prevent Cardiovascular Disease. 2021 , 30, 163-179		8
279	Reduction in Stroke After Transient Ischemic Attack in a Province-Wide Cohort Between 2003 and 2015. 2021 , 48, 335-343		
278	Combating Inflammation in Cardiovascular Disease. 2021 , 30, 197-206		13
277	Cardiovascular risk prediction tools made relevant for GPs and patients. 2020 ,		2
276	Multiclass machine learning vs. conventional calculators for stroke/CVD risk assessment using carotid plaque predictors with coronary angiography scores as gold standard: a 500 participants study. 2021 , 37, 1171-1187		21
275	Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality. 2021 , 134, 643-652		3
274	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. 2021 , 75, e13861		1
273	Nonfasting Lipids for All Patients?. 2021 , 67, 41-45		1
272	Liver Injury Associated With Ezetimibe Monotherapy. 2021 , 3, 195-197		2
271	Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. 2020 , 44, 176		4
270	Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease. 2021 , 1866, 158869		4
269	Use of Preventive Medications in Patients With Nonobstructive Coronary Artery Disease: Analysis of the PROMISE Trial. 2021 , 3, 159-166		1
268	Network Medicine Approach in Prevention and Personalized Treatment of Dyslipidemias. 2021 , 56, 259-268		2
267	Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels. 2021 , 21, 255-265		2
266	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. 2021 , 10, 45		
265	Nutraceuticals and Cardiovascular Disease. 2021 , 67-87		
264	The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease. 2021 , 5, 425-435		2

263	Switching of Hormone Therapies in Breast Cancer Women. 2021 , 43, 185-189		
262	Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib. 2021 , 28, 265-272		1
261	Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. 2021 , 18, e1003498		27
260	Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). 2021 , 28, 159-173		7
259	Coronary CT Angiography Guided Medical Therapy in Subclinical Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
258	Egyptian practical guidance in lipid management 2020. 2021 , 73, 17		3
257	Effects and Issues of Diet Fat on Cardiovascular Metabolism.		
256	Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. 2021 , 11,		1
255	Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies. 2021 , 13,		12
254	Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment. 2021 , 190, 2000-2014		7
253	Effects of vitamin D supplementation on apolipoprotein A1 and B100 levels in adults: Systematic review and meta-analysis of controlled clinical trials. 2021 , 13, 190-197		1
252	Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review. 2021 , 40, 150-164		7
251	Proportions of long-chain Ω fatty acids in erythrocyte membranes of Canadian adults: Results from the Canadian Health Measures Survey 2012-2015. 2021 , 113, 993-1008		3
250	Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology. <i>Current Opinion in Cardiology</i> , 2021 , 36, 272-280	2.1	5
249	RIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study. 2021 , 11, e043612		2
248	Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. 2021 , 77, 1439-1450		32
247	Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors. 2021 , 116, 154706		8
246	Different Lipid Parameters in Predicting Clinical Outcomes in Chinese Statin-Naïve Patients After Coronary Stent Implantation. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 638663	5.4	2

245	A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial. 2021 , 13,		8
244	Survey on lipid diagnostics in Italy from the Working Group on Myocardial Markers (GdS MM) of the Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL): results and recommendations for reporting. 2021 , 17,		
243	Inverse Association of Poultry, Fish, and Plant Protein Consumption with the Incidence of Cardiovascular Disease. 2021 ,		0
242	Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. 2021 ,		9
241	Screening for Lipoprotein(a) Levels in Persons at Low Risk for Cardiovascular Disease: A Teachable Moment. 2021 , 181, 539		3
240	Mechanisms of Atherosclerosis Induced by Postprandial Lipemia. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 636947	5-4	7
239	Real-world implementation of diabetes management by pharmacists: The RING Practice Tool. 2021 , 154, 160-165		0
238	The role of icosapent ethyl in cardiovascular risk reduction. <i>Current Opinion in Cardiology</i> , 2021 , 36, 661-671		0
237	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. 2021 , 14, e006646		4
236	Lipid therapy: A new whiteboard video for patient education. 2021 , 154, 175-178		1
235	Protocol for the WARM Hearts study: examining cardiovascular disease risk in middle-aged and older women - a prospective, observational cohort study. 2021 , 11, e044227		0
234	Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5-1	0
233	Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome. 2021 , 15, 466-476		2
232	Longitudinal changes in adherence to the portfolio and DASH dietary patterns and cardiometabolic risk factors in the PREDIMED-Plus study. 2021 , 40, 2825-2836		3
231	Recent Molecular Mechanisms and Beneficial Effects of Phytochemicals and Plant-Based Whole Foods in Reducing LDL-C and Preventing Cardiovascular Disease. 2021 , 10,		5
230	The gut microbiota is associated with clinical response to statin treatment in patients with coronary artery disease. 2021 , 325, 16-23		3
229	Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. 2021 , 8,		3
228	Prevalence and Functional Implication of Silent Coronary Artery Disease in Marathon Runners Over 40 Years of Age: The MATCH-40 Study. 2021 , 3, 595-602		0

227	Comparison of original and modified Q risk 2 risk score with Framingham risk score - An Indian perspective. 2021 , 73, 353-358		3
226	Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 733-743	3.8	11
225	Role of coronary artery calcium score in the primary prevention of cardiovascular disease. 2021 , 373, n776		12
224	A Snapshot of Lipid-Reporting Practices in Canadian Clinical Laboratories: An Urgent Need for Harmonisation. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 933-937	3.8	0
223	Potential of front face fluorescence spectroscopy and fluorescence imaging in discriminating adulterated extra-virgin olive oil with virgin olive oil. 2021 , 124, 107906		4
222	Management strategies for STE-ACS. 2021 , 46, 18-26		0
221	Impact of the 2016 Canadian Lipid Guidelines on Daily Practice at a Community Hospital. 2021 ,		
220	Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions. 2021 , 23, 44		2
219	A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome. 2021 , 5, bvab114		0
218	Statin therapy for patients with aortic stenosis who underwent transcatheter aortic valve implantation: a report from a Japanese multicentre registry. 2021 , 11, e044319		1
217	The Role of Fasting LDL-C Levels in Their Non-fasting Reduction in Patients With Coronary Heart Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 686234	5.4	0
216	The effect of a 6-month ketogenic medium-chain triglyceride supplement on plasma cardiometabolic and inflammatory markers in mild cognitive impairment. 2021 , 169, 102236		5
215	Lipoprotein (a): Recent Updates on a Unique Lipoprotein. 2021 , 23, 41		3
214	Review of the top 5 cardiology studies of 2019-20. 2021 , 154, 388-393		
213	Who would benefit most from postprandial lipid screening?. 2021 , 40, 4762-4771		1
212	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. 2021 , 42, 4324-4332		14
211	The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?. 2021 , 23, 97		3
210	Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study. 2021 , 328, 92-99		2

209	Treatment Inertia in Patients With Familial Hypercholesterolemia. 2021 , 10, e020126			2
208	Effects of Soy Protein Containing of Isoflavones and Isoflavones Extract on Plasma Lipid Profile in Postmenopausal Women as a Potential Prevention Factor in Cardiovascular Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2021 , 13,			1
207	Evaluation of Statin Use and Prescribing in Patients with Chronic Kidney Disease Not Receiving Treatment with Kidney Transplant or Dialysis. 2021 , 74, 219-226			
206	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. 2021 , 3, 936-949			0
205	A Randomized, Placebo-controlled, Triple-blind Study to Determine the Effect of Farlong Ginseng Plus NotoGinseng Extract on Cholesterol and Blood Pressure. 2021 , 02,			0
204	Non-fasting lipid profile for cardiovascular risk assessments using China ASCVD risk estimator and Europe SCORE risk charts in Chinese participants. 2021 , 11, 991-1001			1
203	Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials. 2021 , 374, n1651			11
202	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1129-1150	3.8		62
201	Comparison of the Reductions in LDL-C and Non-HDL-C Induced by the Red Yeast Rice Extract Xuezhikang Between Fasting and Non-fasting States in Patients With Coronary Heart Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 674446	5.4		0
200	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. 2021 ,			1
199	Relationship Between a Plant-Based Dietary Portfolio and Risk of Cardiovascular Disease: Findings From the Women's Health Initiative Prospective Cohort Study. 2021 , 10, e021515			5
198	Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study. 2021 , 144, 410-422			11
197	British Columbia CARMA-CHIWOS Collaboration (BCC3): protocol for a community-collaborative cohort study examining healthy ageing with and for women living with HIV. 2021 , 11, e046558			0
196	Development of a Portfolio Diet Score and Its Concurrent and Predictive Validity Assessed by a Food Frequency Questionnaire. 2021 , 13,			0
195	Sweet Potato Leaf Feeding Decreases Cholesterol, Oxidative Stress and Thrombosis Formation in Syrian Hamsters with a High-Cholesterol Diet. 2021 , 11,			2
194	Maternal cardiovascular disease after twin pregnancies complicated by hypertensive disorders of pregnancy: a population-based cohort study. 2021 , 193, E1448-E1458			3
193	Lp(a)-Associated Oxidized Phospholipids in Healthy Black and White Participants in Relation to apo(a) Size, Age, and Family Structure. 2021 , 10, e020158			2
192	Low-volume walking HIIT: Efficient strategy to improve physical capacity and reduce the risk of cardiovascular disease in older women with type 2 diabetes. 2021 , 15, 102233			2

191	Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. 2021 , 52, 693-701	1
190	Are fatty nuts a weighty concern? A systematic review and meta-analysis and dose-response meta-regression of prospective cohorts and randomized controlled trials. 2021 , 22, e13330	8
189	Dietary Glycaemic Index Labelling: A Global Perspective. 2021 , 13,	4
188	Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. 2021 , 14, e007485	1
187	Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021. 2021 , 117, 782-844	1
186	Dietary Lipids and Dyslipidemia in Chronic Kidney Disease. 2021 , 13,	2
185	Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. 2021 , 96, 1-7	0
184	Relaci3n del envejecimiento vascular saludable con los estilos de vida y el s3ndrome metab3lico en poblaci3n general espa3ola. Estudio EVA. 2021 , 74, 854-861	0
183	Development of Fatty Acid Reference Ranges and Relationship with Lipid Biomarkers in Middle-Aged Healthy Singaporean Men and Women. 2021 , 13,	1
182	Rottura dell'aneurisma dell'orta addominale: tecniche specifiche. 2021 , 26, 1-25	
181	Elevated lipoprotein(a) and risk of coronary heart disease according to different lipid profiles in the general Chinese community population: the CHCN-BTH study. 2021 , 9, 26	3
180	Assessing the dyslipidemias: to fast or not to fast?. 2021 , 28, 97-103	1
179	Rupturas de aneurisma de la aorta abdominal: t3cnicas espec3ficas. 2021 , 21, 1-26	
178	Multi-omics study reveals that statin therapy is associated with restoration of gut microbiota homeostasis and improvement in outcomes in patients with acute coronary syndrome. 2021 , 11, 5778-5793	10
177	Optimum lipid testing for diabetic patients to enhance clinical care. 2021 , 15, 461-464	1
176	Elevated Lipoprotein(A) in Children and Adolescents: Early Identification is Key for Successful Intervention. 2021 , 34, 19-20	
175	Statin-Associated Muscle Symptoms Are Real. 2020 , 5-19	1
174	Hypertensive Disorders of Pregnancy and Cardiovascular Diseases: Current Knowledge and Future Directions. 2018 , 20, 56	29

173	Statins for primary prevention in adults aged 75 years and older: A nationwide population-based case-control study. 2019 , 283, 28-34		14
172	Pediatric Dyslipidemia-Beyond Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1362-1371	3.8	3
171	Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. 2020 ,		11
170	Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial. 2020 , 134, 185-192		6
169	Lipoprotein (a) and diabetes mellitus: causes and consequences. 2021 , 28, 181-187		3
168	Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions.		1
167	Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. 2020 , 7,		5
166	Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments. 2018 , 15, e1002539		7
165	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. 2020 , 15, e0240567		3
164	Lipoprotein(a) - Link between Atherogenesis and Thrombosis. 2019 , 120, 39-51		6
163	[Lipid-Lowering Therapy for Primary Cardiovascular Prevention in Older Adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists]. 2020 , 60, 1037		4
162	Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors. 2020 , 27, 4494-4521		0
161	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. 2020 , 27, 1021-1040		10
160	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. 2019 , 17, 515-537		12
159	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. 2019 , 17, 498-514		23
158	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice. 2020 , 16, 949-956		2
157	Integration of estimated glomerular filtration rate biomarker in image-based cardiovascular disease/stroke risk calculator: a south Asian-Indian diabetes cohort with moderate chronic kidney disease. 2020 , 39, 290-306		12
156	Simvastatin inhibits the adipogenesis of bone marrow-derived mesenchymal stem cells through the downregulation of chemerin/CMKLR1 signaling. 2020 , 46, 751-761		2

155	Awareness of cardiovascular disease associated risk factors among Saudis in Riyadh City. 2020 , 9, 3100-3105	5
154	Awareness of Physicians and Clinical Pharmacists About ACC/AHA Guidelines for Dyslipidemia Management: A Cross-Sectional Study. 2019 , 11, 181-186	4
153	Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. 2019 , 24, 15	15
152	Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-2015). 2020 , 24, 91-98	3
151	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. 2019 , 113, 787-891	29
150	Postprandial dyslipidemia in insulin resistant states in adolescent populations. 2020 , 34, 328-342	2
149	Cardiovascular Risk Factor Modification in Asymptomatic Adults and Implications for Pilots. 2020 , 42, 187-201	2
148	Reduction in Serum LDL Cholesterol Using a Nutrient Compendium in Hyperlipidemic Adults Unable or Unwilling to Use Statin Therapy: A Double-Blind Randomized Crossover Clinical Trial.. 2022 ,	
147	Serum lipid profile based on the prandial state among adult subjects. 2021 , 15, 15-21	
146	Which Diets Are Effective in Reducing Cardiovascular and Cancer Risk in Women with Obesity? An Integrative Review. 2021 , 13,	2
145	Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018.. 2022 , 4, 206-213	1
144	Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?. 2021 , 99, 60-60	0
143	Online clinical pathway for chronic kidney disease management in primary care: a retrospective cohort study. 2021 , 22, 332	1
142	The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk. 2017 , 108, 518-525	2
141	The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia. 2017 , 5, 477	
140	Pharmacoepidemiology of statins in East region of Kazakhstan. 2018 , 1, 36-40	
139	The year in cardiology 2017: prevention. 2018 , 13, 79-98	
138	RAISED LEVEL OF LIPOPROTEIDE(A) AS A PREDICTOR OF CARDIOVASCULAR COMPLICATION POST REVASCULARIZATION OF THE LOWER EXTREMITIES ARTERIES. 2018 , 7-12	

137	Nutrition, Health and Dietary Trends. 2019 , 63-82		
136	Serum chemerin as a predictor of left ventricle hypertrophy in patients with coronary artery disease. 2019 , 16, 25		
135	Clinical Care for Individuals with Chronic Trypanosoma cruzi Infection: Decision-Making in the Midst of Uncertainty. 2019 , 199-224		1
134	Monitoring patients with systemic lupus erythematosus: general characteristics and discussion questions (according to the Canadian Rheumatology Association recommendations). 2019 , 57, 255-264		2
133	[Statins in elderly patients in 2018: When, how, and why]. 2019 , 54, 249-250		
132	Accurate Prediction of Coronary Heart Disease for Patients With Hypertension From Electronic Health Records With Big Data and Machine-Learning Methods: Model Development and Performance Evaluation (Preprint).		
131	Chronic Kidney Disease and End Stage Renal Disease. 2020 , 45-115		
130	Association of Increased Remnant Cholesterol and the Risk of Coronary Artery Disease: A Retrospective Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 740596	5-4	0
129	Common Bean Baked Snack Consumption Reduces Apolipoprotein B-100 Levels: A Randomized Crossover Trial. 2021 , 13,		3
128	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. 2021 , 28, 104-113		
127	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. 2021 , 139-158		0
126	Display of Microbial Glucose Dehydrogenase and Cholesterol Oxidase on the Yeast Cell Surface for the Detection of Blood Biochemical Parameters. 2020 , 11,		2
125	C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis. 2021 , 565-583		1
124	Genetic Disorders of Lipoprotein Metabolism. 2021 , 35-80		
123	Cholesterol Absorption. 2020 , 503-513		
122	Introduction. 2020 , xv-xix		
121	The Canadian Consensus Working Group's Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. 2020 , 137-150		
120	Non-HDL cholesterol level and depression among Canadian elderly: cross-sectional analysis of the baseline data from the CLSA. 2020 , 5, 1006-1018		

- 119 Atherogenic dyslipidemia typical for metabolic syndrome. **2020**, 66, 15-20
- 118 Triglyceride and Glucose Index and Sex Differences in Relation to Major Adverse Cardiovascular Events in Hypertensive Patients Without Diabetes. *Frontiers in Endocrinology*, **2021**, 12, 761397 5-7 2
- 117 The Correlation Between Lipid Profile and Xanthelasma. **2020**, 32, 119
- 116 Changing dietary approaches to prevent cardiovascular disease. **2020**, 31, 313-323 3
- 115 Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors. **2021**, 46, 415-423 1
- 114 Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment. **2017**, 28, 168-184 28
- 113 Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. **2017**, 63, e495-e503 16
- 112 Do PCSK9 inhibitors reduce cardiovascular events?. **2018**, 64, 669
- 111 Approach to the detection and management of chronic kidney disease: What primary care providers need to know. **2018**, 64, 728-735 15
- 110 Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes. **2019**, 65, 14-24 16
- 109 . **2019**, 65, e8-e18
- 108 . **2019**, 65, e251-e260 2
- 107 Normal-weight central obesity: Unique hazard of the toxic waist. **2019**, 65, 399-408 12
- 106 Pregnancy-related cardiovascular risk indicators: Primary care approach to postpartum management and prevention of future disease. **2019**, 65, 883-889 4
- 105 . **2019**, 65, e505-e512
- 104 Update to the Preventive Care Checklist Form. **2020**, 66, 270-272
- 103 Genosets for APOE and CYP7A1-rs3808607 variants do not predict low-density lipoprotein cholesterol lowering upon intervention with plant sterols in a randomized, double-blind, placebo-controlled trial. **2021**,
- 102 Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD.. **2022**, 9,

101	Applications of Microbial Fermentation to Food Products, Chemicals and Pharmaceuticals. 2021 , 173-577	
100	Control of Cardiovascular Risk Factors in Patients with Chronic Obstructive Pulmonary Disease.. 2022 ,	0
99	Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study.. 2021 , 341, 20-26	0
98	Physical Activity and Nutrition in Chronic Kidney Disease. 2022 , 323-363	
97	The Association of Heart/Vascular Aging with Mild Cognitive Impairment in a Rural Multiethnic Cohort: The Project FRONTIER Study.. 2022 , 9, 315-322	
96	High-density lipoprotein, low-density lipoprotein and triglyceride levels and upper gastrointestinal cancers risk: a trans-ancestry Mendelian randomization study.. 2022 ,	0
95	Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting.. 2021 , 109177	0
94	Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.. 2022 , 2022, 8129513	3
93	Disorders of Lipoprotein Metabolism. 2022 , 1035-1055	
92	Lipid management. 2022 , 400-418	
91	Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L.. 2022 , 33197221075861	
90	Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids.. 2021 , 8, 768474	1
89	The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries: A Review.. 2022 , 17, 18	0
88	The impact of mobile application: "Friends of Heart" in knowledge and compliance of patients with coronary heart disease. 36-40	
87	A Bayesian Network Analysis of the Probabilistic Relationships Between Various Obesity Phenotypes and Cardiovascular Disease Risk in Chinese Adults: Chinese Population-Based Observational Study.. 2022 , 10, e33026	0
86	Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study.. 2022 , 4, 85-94	5
85	How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?. 2022 ,	0
84	Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. 2022 ,	0

83	Medical nutrition therapy for chronic pain management. 2022 , 147-159		
82	A Powerful Paradigm for Cardiovascular Risk Stratification Using Multiclass, Multi-Label, and Ensemble-Based Machine Learning Paradigms: A Narrative Review.. 2022 , 12,		3
81	Adverse Pregnancy Outcomes and Maternal Chronic Diseases in the Future: A Cross-Sectional Study Using KoGES-HEXA Data.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
80	Impact of Lipoprotein(a) concentrations on long-term cardiovascular outcomes in patients undergoing percutaneous coronary intervention: A large cohort study.. 2022 ,		
79	Canadian Society of Clinical Chemists (CSCC) Harmonized Clinical Laboratory Lipid Reporting Recommendations based on 2021 Canadian Cardiovascular Society Lipid Guidelines.. <i>Canadian Journal of Cardiology</i> , 2022 ,	3.8	0
78	A Bayesian Network Analysis of the Probabilistic Relationships Between Various Obesity Phenotypes and Cardiovascular Disease Risk in Chinese Adults: Chinese Population-Based Observational Study (Preprint).		
77	Atherosclerosis and cardiovascular risk in patients with inflammatory bowel disease. 2021 , 93, 1533-1538		1
76	Statins for primary prevention among elderly men and women. 2021 ,		2
75	Quality improvement and usability testing of the PortfolioDiet.app, a web-based health application to translate nutrition therapy for cardiovascular risk reduction in primary care (Preprint).		
74	Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 807925	5.4	0
73	Modifiable Risk Factors and Residual Risk Following Coronary Revascularization: Insights From a Regionalized Dedicated Follow-Up Clinic.. 2021 , 5, 1138-1152		1
72	A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study.. 2022 , 9, e34704		0
71	Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study.. 2022 , 79, 1579-1590		4
70	Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial.. 2022 , 14, 52		2
69	Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal Study.. 2022 , 22, 558		
68	Data_Sheet_1.docx. 2019 ,		
67	Effect of an Exercise and Nutrition Program on Quality of Life in Patient with Atrial Fibrillation: The Atrial Fibrillation Lifestyle Project (ALP). 2022 ,		
66	Association Between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 877140	5.4	1

65	Hypertriglyceridemia in young adults with a 22q11.2 microdeletion.. 2022 , 187, 91-99		o
64	How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?. 2022 , e023578		o
63	Cardiovascular Risk Stratification in Diabetic Retinopathy via Atherosclerotic Pathway in COVID-19/non-COVID-19 Frameworks using Artificial Intelligence Paradigm: A Narrative Review. 2022 , 12, 1234		1
62	Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.. 2022 , 22, 342		o
61	Food behaviors accounting for the recent trends in dietary fatty acid profiles among Korean adults. 2022 , 16, 405		
60	Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis.		
59	Short-term effects of modest salt reduction combined with DASH diet on changing salt eating habits in hypertensive patients with type II diabetes. 1-9		o
58	A cross-sectional study evaluating cardiovascular risk and statin prescribing in the Canadian Primary Care Sentinel Surveillance Network database. 2022 , 23,		o
57	Using big data for cardiovascular health surveillance: Insights from 10.3 million individuals in the CANHEART cohort. <i>Canadian Journal of Cardiology</i> , 2022 ,	3.8	o
56	Circulating level of homocysteine contributes to diabetic retinopathy associated with dysregulated lipid profile and impaired kidney function in patients with type 2 diabetes mellitus. <i>Eye</i> ,	4.4	o
55	The Association Between Route of Post-menopausal Estrogen Administration and Blood Pressure and Arterial Stiffness in Community-Dwelling Women. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	o
54	Diet and vascular risk. <i>Current Opinion in Cardiology</i> , 2022 , 37, 343-349	2.1	
53	Low Prevalence of Cardiomyopathy in Patients with Mitochondrial Disease and Neurological Manifestations. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 221	4.2	1
52	Machine-Learning Score Using Stress CMR for Death Prediction in Patients With Suspected or Known CAD. <i>JACC: Cardiovascular Imaging</i> , 2022 ,	8.4	o
51	The Inherited Hypercholesterolemias. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022 ,	5.5	o
50	Lipid Profile, Lp(a) Levels, and HDL Quality in Adolescents with Down Syndrome. <i>Journal of Clinical Medicine</i> , 2022 , 11, 4356	5.1	o
49	Meal Replacements for Weight-Related Complications in Type 2 Diabetes: What Is the State of the Evidence?. <i>Frontiers in Endocrinology</i> , 13,	5.7	o
48	Cost-Effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention.		o

47	Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. 2022 , 20, 609-625	0
46	Maternal Immune Cell and Cytokine Profiles to Predict Cardiovascular Risk Six Months after Preeclampsia. 2022 , 11, 4185	
45	Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study. 2022 ,	
44	Low Subjective Cardiovascular Disease Risk Perceptions among Hypertensive Patients in Addis Ababa, Ethiopia. Volume 15, 81-96	0
43	Prognostic values of modifiable risk factors for cardiovascular events in South African health promotion. 2022 , 17, e0271169	0
42	Nordic dietary patterns and cardiometabolic outcomes: a systematic review and meta-analysis of prospective cohort studies and randomised controlled trials.	1
41	Are all fibres created equal with respect to lipid lowering? Comparing the effect of viscous dietary fibre to non-viscous fibre from cereal sources: a systematic review and meta-analysis of randomised controlled trials. 1-13	0
40	Deep learning artificial intelligence framework for multiclass coronary artery disease prediction using combination of conventional risk factors, carotid ultrasound, and intraplaque neovascularization. 2022 , 150, 106018	0
39	Relationship between lipoprotein (a) and subclinical carotid atherosclerosis in asymptomatic individuals. 2022 , 77, 100107	0
38	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. 2022 ,	2
37	The Risk of Cardiovascular Disease According to Chewing Status Could Be Modulated by Healthy Diet in Middle-Aged Koreans. 2022 , 14, 3849	0
36	Effect of Important Food Sources of Fructose-Containing Sugars on Inflammatory Biomarkers: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. 2022 , 14, 3986	0
35	Lipoprotein a Combined with Fibrinogen as an Independent Predictor of Long-Term Prognosis in Patients with Acute Coronary Syndrome: A Multi-Center Retrospective Study. 2022 , 9, 322	0
34	Lack of age-appropriate reference intervals causing potentially missed alerts in clinical reports of dyslipidemia. 2022 ,	0
33	Predicted heart age profile across 41 countries: A cross-sectional study of nationally representative surveys in six world regions. 2022 , 101688	0
32	Combining elements of the CO-OP Approach with education to promote healthy eating among older adults: A pilot study. 3,	0
31	Non-traditional lipid parameters as potential predictors of carotid plaque vulnerability and stenosis in patients with acute ischemic stroke.	0
30	Using polygenic risk scores for prioritising individuals at greatest need of a CVD risk assessment.	0

- 29 The prevalence of documented cardiovascular-related pregnancy complications: cross-sectional study in an academic primary care centre. BJJPO.2022.0070 ○
- 28 Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial. 9, ○
- 27 Exploring the Novelty in Lipid Profiling of Patients: A Non-fasting Approach from Eastern India. ○
- 26 Joint effects of carotid plaques and renal impairment on the risk of cardiovascular disease and all-cause death in a community-based population: The Kailuan cohort study. 9, ○
- 25 Fasting and non-fasting lipoproteins and apolipoproteins for long-term outcome prediction in Chinese patients with coronary heart disease:a prospective observational study. ○
- 24 Lipoprotein(a) and Cardiovascular Disease in Chinese Population. **2022**, 2, 653-665 ○
- 23 Lp(a) does not affect intima media thickness in hypercholesterolemic children & retrospective cross sectional study. **2023**, 51, 1-7 ○
- 22 Undergraduate Medical Students' Perceptions of Nutrition Education at the Northern Ontario School of Medicine. 1-5 ○
- 21 Effects of lifestyle interventions on cardiovascular risk factors in South Asians: a systematic review and meta-analysis. **2022**, 12, e059666 ○
- 20 Recommended and Observed Statin Use among U.S. Adults [National Health and Nutrition Examination Survey, 2011-2018. **2022**, ○
- 19 Primary Care Clinical Volumes, Cholesterol Testing, and Cardiovascular Outcomes. **2022**, ○
- 18 Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions. Volume 19, 31-41 ○
- 17 Important food sources of fructose-containing sugars and adiposity: A systematic review and meta-analysis of controlled feeding trials. **2023**, 117, 741-765 ○
- 16 Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population. **2023**, 372, 1-9 ○
- 15 Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population. **2023**, 233, 123586 ○
- 14 Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model. 14, ○
- 13 Nuts and Cardiovascular Disease Outcomes: A Review of the Evidence and Future Directions. **2023**, 15, 911 ○
- 12 U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults. **2023**, ○

- 11 When Should We Measure Lipoprotein(a)? **2023**, 275-280
- 10 Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease. **2023**,
- 9 Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis. **2023**, 11, 43
- 8 Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. **2023**, 329, 1078
- 7 Management of Stable Angina: A Treatment Strategy Mnemonic. **2023**, 104473
- 6 Development of ALOHa-G Risk Score for Detecting Postpartum Dyslipidemia Among Normoglycemic Women with Previous Gestational Diabetes: Observational Cohort Study.
- 5 A Systematic Review on the Risk Modulators of Myocardial Infarction in the Young Implications of Lipoprotein (a). **2023**, 24, 5927
- 4 Adherence to cardiovascular prevention guidelines in an academic center. **2023**,
- 3 A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. 14,
- 2 Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada. Volume 15, 295-308
- 1 Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. 171516352311649